Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.58 |
| ▸ | STAT6 | P42226 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 12/20 | 0.34 |
| ▸ | MMP13 | P45452 | 8/20 | 0.34 |
| ▸ | MMP2 | P08253 | 6/20 | 0.33 |
| ▸ | MMP3 | P08254 | 5/20 | 0.33 |
| ▸ | MMP8 | P22894 | 3/20 | 0.33 |
| ▸ | MMP12 | P39900 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368748 | 0.93 | TUBB1 (0.60) | TUBB1STAT6MMP1MMP13MMP2 | |
| SCHEMBL4368386 | 0.91 | TUBB1 (0.57) | TUBB1STAT6MMP1MMP13MMP2 | |
| SCHEMBL6809684 | 0.84 | TUBB1 (0.59) | TUBB1STAT6MMP1MMP2MMP3 | |
| SCHEMBL88443 | 0.84 | TUBB1 (0.59) | TUBB1STAT6MMP1MMP2MMP3 | |
| SCHEMBL57945 | 0.84 | TUBB1 (0.59) | TUBB1STAT6MMP1MMP2MMP3 | |
| SCHEMBL4366955 | 0.82 | TUBB1 (0.62) | TUBB1STAT6MMP1MMP2MMP3 | |
| SCHEMBL13585784 | 0.82 | TUBB1 (0.62) | TUBB1STAT6MMP1MMP2MMP3 | |
| SCHEMBL4379894 | 0.82 | TUBB1 (0.66) | TUBB1STAT6MMP1MMP13MMP2 | |
| SCHEMBL4367494 | 0.81 | TUBB1 (0.57) | TUBB1STAT6MMP1MMP2MMP3 | |
| SCHEMBL58290 | 0.80 | TUBB1 (0.74) | TUBB1STAT6MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626023-B2 | Compounds for treating tumors | WYETH (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2005016958-A2 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050037977-A1 | Compounds for treating tumors | WYETH HOLDINGS CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | RB1, MRPL9, BCOR | TUBB1 588/4885STAT6 972/4885MMP1 3418/4885 |
| US-20050037977-A1 | Compounds for treating tumors | RB1, MRPL9, BCOR | TUBB1 588/4885STAT6 972/4885MMP1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.